Verismo Presents Preclinical Data at SITC 2026
The company said its SynKIR™ KIR-CAR showed faster tumor control and approximately 10-fold lower IFNγ, with 30-fold lower cytokine release, than conventional CAR T.
The company said its SynKIR™ KIR-CAR showed faster tumor control and approximately 10-fold lower IFNγ, with 30-fold lower cytokine release, than conventional CAR T.